Best Cancer Screening Tests in 2026
Multi-cancer early detection (MCED) tests represent a paradigm shift in cancer screening. Instead of testing for one cancer at a time, these blood tests scan for signals from dozens of cancer types simultaneously. We compared six tests a person without a cancer diagnosis can order, from established tests like Cologuard for colon cancer to liquid biopsies like Galleri that look for signals from 50+ cancers. Published cash prices run from $790 (Cologuard) to $1,495 (Shield); Galleri lists at $949. The technology is advancing rapidly, but not all tests have equal clinical validation. Some have FDA approval while others operate as laboratory-developed tests. This guide explains what current tests can and cannot detect, and who should consider screening beyond standard guidelines.
Quick comparison
At a glance. Each row links to the full pick below.
| Rank | Provider | Price | Best for |
|---|---|---|---|
| 01 | Galleri by GRAIL | $949 | High-risk individuals wanting comprehensive screening |
| 02 | Shield by Guardant | $1,495 | Adults 45+ wanting non-invasive CRC screening |
| 03 | Cologuard by Exact Sciences | $790 | Adults 45+ preferring home collection for CRC screening |
| 04 | Freenome | Variable | Average-risk adults 45+ wanting blood-based colorectal screening |
| 05 | Delfi Diagnostics | Variable | Adults 50-80 with a 20 pack-year smoking history, alongside low-dose CT |
| 06 | Prenetics CIRCLE | Varies | People who want to know their inherited cancer risk |
Top picks
Ranked in the order above, with what each one gets right and where it falls short.
Detects a signal shared by 50+ cancers. GRAIL leads with 76.3% sensitivity across the 12 cancers causing two-thirds of US cancer deaths (pancreatic 83.7%, liver/bile duct 93.5%, ovary 83.1%). PPV ~62%, cancer signal origin accuracy 93.4%. List $949; a self-pay promotion ($699 online, $599 through a provider) runs through 31 December 2026. Not covered by Medicare or most plans; assistance up to $350 off at or below 400% FPL. Not FDA approved: the 23 September 2026 advisory panel voted 7-2 that benefits outweigh risks (unanimous on safety, 6-4 on effectiveness). The vote is not binding; GRAIL expects the FDA's decision in the coming months.
First FDA-approved blood test for primary colorectal cancer screening. $1,495 cash pay; most insured patients pay $0. Medicare covered, UnitedHealthcare coverage added, VA Community Care covered. ADLT status from CMS. Detects only 13% of advanced adenomas. Note: Guardant's separate Shield MCD multi-cancer test is NOT FDA approved and is a different product at a different price.
Cologuard Plus is the current flagship: 95% sensitivity for Stage I-IV CRC, 94% specificity, detects 43% of advanced precancerous lesions. Self-pay $790. $0 for eligible Medicare Part B members 45-85 and ACA-eligible patients 45-75; free at or below 400% FPL. The older original Cologuard (92%/87%) is a separate legacy product. Exact Sciences was acquired by Abbott, closing 23 March 2026.
SimpleScreen CRC won FDA approval on 27 July 2026 for average-risk adults 45+: 81.1% CRC sensitivity, 90.4% specificity, 13.7% for advanced precancerous lesions. Blood-based cfDNA with AI/ML, validated in PREEMPT CRC (48,000+ participants). Abbott launched it in the US on 30 September 2026 as exclusive commercial partner; price and turnaround are not published. Included in the updated ACS colorectal screening guideline.
Delfi Diagnostics
Best for: Adults 50-80 with a 20 pack-year smoking history, alongside low-dose CT
Novel fragmentomics approach - applies machine learning to whole-genome sequencing of cfDNA fragmentation patterns. Complements rather than replaces low-dose CT screening. 99.8% negative predictive value; an elevated result raises the likelihood of finding lung cancer on LDCT by 5.2x. For adults 50-80 with a 20 pack-year smoking history. CLIA LDT, not FDA approved. Now authorised in all 50 states following its New York State permit in 2026.
IMPORTANT: this is a hereditary risk test, not active cancer detection. CircleDNA is a consumer whole-exome saliva test whose Cancer Screening Report assesses inherited predisposition across 35+ cancers - it does not detect existing cancer. Hong Kong based (Prenetics Global, NASDAQ: PRE); pricing is served in HKD and varies by region. Prenetics sold its remaining stake in Insighta, maker of the Presight blood-based multi-cancer test, to Tencent in February 2026.
How we chose these picks
Questions people ask
What's the difference between Galleri and traditional cancer screening?
Traditional screening tests (mammograms, colonoscopies, PSA tests) look for one specific cancer each. Galleri analyzes cell-free DNA in blood to detect signals from 50+ cancer types, including many without standard screening tests. Galleri supplements rather than replaces traditional screening. Its strength is finding cancers that would otherwise be detected only after symptoms appear, often at later stages.
How accurate are multi-cancer early detection tests?
In GRAIL's CCGA validation study, Galleri detected 51.5% of cancers overall, rising with stage from 16.8% at stage I to 90.1% at stage IV, with 99.5% specificity (Klein et al., Ann Oncol 2021). In the PATHFINDER 2 study of 32,007 adults aged 50 and older, it detected 39.3% of cancers diagnosed within a year, with 99.64% specificity (Nabavizadeh et al., Nat Med 2026). For specific cancers, traditional screening may be more sensitive, but MCED catches cancers that lack any screening option. No test catches everything, and negative results don't guarantee you're cancer-free.
Who should consider multi-cancer screening tests?
People at elevated cancer risk due to age (50+), family history, or genetic predisposition may benefit most. Those with access to timely follow-up care get more value since positive results require additional testing. MCED tests are not recommended as the only screening approach since they complement but don't replace colonoscopy, mammography, and other proven screens. Cost and insurance coverage also factor into the decision.
What happens if a multi-cancer test is positive?
A positive result triggers additional diagnostic testing to locate and confirm the cancer. MCED tests predict the likely cancer origin, but imaging and potentially biopsy confirm the finding. This process may involve weeks of uncertainty and multiple appointments. In PATHFINDER 2, 60.3% of positive Galleri results led to a cancer diagnosis, so about 4 in 10 positive results did not (Nabavizadeh et al., Nat Med 2026). Discuss the implications with your doctor before testing.
Are these tests covered by insurance?
Coverage varies significantly. Cologuard for colorectal screening is widely covered. Newer MCED tests like Galleri typically aren't covered by insurance or Medicare. Some employers and concierge medicine practices include them in health benefits. Galleri lists at $949 without coverage. As clinical evidence accumulates, coverage is expected to expand over the next several years.
Compare all options and find the fit for your health goals.
View all Cancer Screening optionsThis comparison is for informational purposes only and is not medical advice. Prices were last checked against each provider's own site (Nov 18, 2026) and may have changed since. Consult a healthcare provider before making health-related decisions.